These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 39044673)

  • 41. Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis: A Randomized Clinical Trial.
    Worm M; Simpson EL; Thaçi D; Bissonnette R; Lacour JP; Beissert S; Kawashima M; Ferrándiz C; Smith CH; Beck LA; Chan KC; Chen Z; Akinlade B; Hultsch T; Staudinger H; Gadkari A; Eckert L; Davis JD; Rajadhyaksha M; Graham NMH; Pirozzi G; Stahl N; Yancopoulos GD; Ardeleanu M
    JAMA Dermatol; 2020 Feb; 156(2):131-143. PubMed ID: 31876900
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Efficacy and safety of dupilumab in the treatment of moderate to severe atopic dermatitis].
    Wang JY; Zhou BJ; Cao QZ; Peng C; Chen ML; Chen X; Li J
    Zhonghua Yi Xue Za Zhi; 2024 Aug; 104(30):2810-2816. PubMed ID: 39085148
    [No Abstract]   [Full Text] [Related]  

  • 43. Treatment of atopic dermatitis with dupilumab: experience from a tertiary referral centre.
    Olesen CM; Holm JG; Nørreslet LB; Serup JV; Thomsen SF; Agner T
    J Eur Acad Dermatol Venereol; 2019 Aug; 33(8):1562-1568. PubMed ID: 30959559
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dupilumab Treatment in Children Aged 6-11 Years With Atopic Dermatitis: A Multicentre, Real-Life Study.
    Napolitano M; Fabbrocini G; Neri I; Stingeni L; Boccaletti V; Piccolo V; Amoruso GF; Malara G; De Pasquale R; Di Brizzi EV; Diluvio L; Bianchi L; Chiricozzi A; Di Guida A; Del Duca E; Moschese V; Di Lernia V; Dragoni F; Gruber M; Hansel K; Licari A; Manti S; Leonardi S; Mastorino L; Ortoncelli M; Provenzano E; Palermo A; Patella V; Peduto T; Pezzolo E; Piras V; Potestio L; Battista T; Satta R; Termine S; Palma P; Zangari P; Patruno C
    Paediatr Drugs; 2022 Nov; 24(6):671-678. PubMed ID: 36028611
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dupilumab Safety and Efficacy up to 1 Year in Children Aged 6 Months to 5 Years with Atopic Dermatitis: Results from a Phase 3 Open-Label Extension Study.
    Paller AS; Siegfried EC; Simpson EL; Cork MJ; Sidbury R; Chen IH; Khokhar FA; Xiao J; Dubost-Brama A; Bansal A
    Am J Clin Dermatol; 2024 Jul; 25(4):655-668. PubMed ID: 38743155
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Long-term, observational, real-world study of dupilumab for the treatment of moderate-to-severe atopic dermatitis: a 52-week single-center retrospective analysis in China.
    Deng S; Wang H; Chen Q; Chen X; Song X; Chen S; Kong M; Song Z
    Arch Dermatol Res; 2024 May; 316(6):304. PubMed ID: 38819652
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dupilumab in daily practice for the treatment of pediatric atopic dermatitis: 28-week clinical and biomarker results from the BioDay registry.
    Kamphuis E; Boesjes CM; Loman L; Bakker DS; Poelhekken M; Zuithoff NPA; Kamsteeg M; Romeijn GLE; van Wijk F; de Bruin-Weller MS; de Graaf M; Schuttelaar MLA
    Pediatr Allergy Immunol; 2022 Dec; 33(12):e13887. PubMed ID: 36564878
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Switching between JAK Inhibitors in Patients with Atopic Dermatitis: Unanswered Questions in Daily Clinical Practice.
    Mastraftsi S; Bakakis M; Tsiogka A; Afroditi Kleidona I; Gregoriou S
    Acta Dermatovenerol Croat; 2023 Dec; 31(3):162-164. PubMed ID: 38439732
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Clinical observation on the efficacy and safety of dupilumab in the treatment of moderate to severe atopic dermatitis].
    Li CY; Chen S; Qian WL; Yang L; Zheng Q; Chen AJ; Chen J; Huang K; Fang S; Wang P; Hu L; Liu XR; Zhao XQ; Tan N; Cai T
    Zhonghua Yu Fang Yi Xue Za Zhi; 2023 Oct; 57(10):1590-1595. PubMed ID: 37859375
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Long-term effectiveness and safety of treatment with dupilumab in patients with atopic dermatitis: Results of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry.
    Bosma AL; de Wijs LEM; Hof MH; van Nieuwenhuizen BR; Gerbens LAA; Middelkamp-Hup MA; Hijnen D; Spuls PI
    J Am Acad Dermatol; 2020 Nov; 83(5):1375-1384. PubMed ID: 32485210
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE).
    Blauvelt A; Guttman-Yassky E; Paller AS; Simpson EL; Cork MJ; Weisman J; Browning J; Soong W; Sun X; Chen Z; Kosloski MP; Kamal MA; Delevry D; Chuang CC; O'Malley JT; Bansal A
    Am J Clin Dermatol; 2022 May; 23(3):365-383. PubMed ID: 35567671
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A 24-weeks real-world experience of dupilumab in adolescents with moderate-to-severe atopic dermatitis.
    Napolitano M; Fabbrocini G; Potestio L; Fontanella G; Picone V; Bennardo L; Scalvenzi M; Patruno C
    Dermatol Ther; 2022 Aug; 35(8):e15588. PubMed ID: 35569129
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy of Dupilumab in Different Racial Subgroups of Adults With Moderate-to-Severe Atopic Dermatitis in Three Randomized, Placebo-Controlled Phase 3 Trials.
    Alexis AF; Rendon M; Silverberg JI; Pariser DM; Lockshin B; Griffiths CE; Weisman J; Wollenberg A; Chen Z; Davis JD; Li M; Eckert L; Gadkari A; Shumel B; Rossi AB; Graham NM; Ardeleanu M
    J Drugs Dermatol; 2019 Aug; 18(8):804-813. PubMed ID: 31424712
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ).
    de Bruin-Weller M; Thaçi D; Smith CH; Reich K; Cork MJ; Radin A; Zhang Q; Akinlade B; Gadkari A; Eckert L; Hultsch T; Chen Z; Pirozzi G; Graham NMH; Shumel B
    Br J Dermatol; 2018 May; 178(5):1083-1101. PubMed ID: 29193016
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cost-effectiveness analysis of baricitinib versus dupilumab for moderate to severe atopic dermatitis: an Italian healthcare system perspective.
    Johansson E; Giovannitti M; Mezzetti M; Lu N; Sabatino S
    J Med Econ; 2023; 26(1):1155-1166. PubMed ID: 37674383
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Drug survival rates and reasons for drug discontinuation in patients with atopic dermatitis: a retrospective study of adult outpatients.
    Pino Lopez J; Kromer C; Herr R; Schmieder A; Bayerl C; Schaarschmidt ML
    Eur J Dermatol; 2021 Apr; 31(2):233-238. PubMed ID: 33871362
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Successful Combination of Systemic Agents for the Treatment of Atopic Dermatitis Resistant to Dupilumab Therapy.
    Gori N; Chiricozzi A; Malvaso D; D'Urso DF; Caldarola G; De Simone C; Peris K
    Dermatology; 2021; 237(4):535-541. PubMed ID: 33477153
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy and Safety of Dupilumab in Patients With Erythrodermic Atopic Dermatitis: A Post Hoc Analysis of 6 Randomized Clinical Trials.
    Paller AS; Silverberg JI; Cork MJ; Guttman-Yassky E; Lockshin B; Irvine AD; Kim MB; Kabashima K; Chen Z; Lu Y; Bansal A; Rossi AB; Shabbir A
    JAMA Dermatol; 2023 Mar; 159(3):255-266. PubMed ID: 36723913
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy and Safety of Dupilumab for the Treatment of Severe Atopic Dermatitis in Clinical Practice: A Single Center Experience.
    Martínez-Doménech A; Zaragoza-Ninet V; Esteve-Martínez A; García-Rabasco A; Sánchez-Carazo JL; Pérez-Ferriols A
    Actas Dermosifiliogr; 2024 Feb; 115(2):T150-T158. PubMed ID: 38048951
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy and Safety of Dupilumab for the Treatment of Severe Atopic Dermatitis in Clinical Practice: A Single Center Experience.
    Martínez-Doménech A; Zaragoza-Ninet V; Esteve-Martínez A; García-Rabasco A; Sánchez-Carazo JL; Pérez-Ferriols A
    Actas Dermosifiliogr; 2024 Feb; 115(2):150-158. PubMed ID: 37858860
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.